Urgently ask for the important event about drugs that happened in China on April 2065438+02-March 2065438. Thank you! ! ! !

1, the industry growth rate slowed down, and the profit growth rate lagged behind the output growth rate.

In 20 12, the main business income of pharmaceutical industry was1708.3 billion yuan, and the total profit was173.2 billion yuan, up by 20% and 19% respectively. The year-on-year growth rate of main business income is from fast to slow, followed by traditional Chinese medicine decoction pieces, traditional Chinese medicine preparations, chemical preparations, medical devices, biological products and chemical raw materials; The year-on-year growth rate of total profit is medical devices, chemical preparations, Chinese herbal pieces, Chinese herbal preparations, biological products and chemical raw materials. National Bureau of Statistics(NBS)

2. The "poison capsule" incident triggered a crisis of confidence in the industry.

On April 2012 15, CCTV's Weekly Quality Report broadcast the program "Secrets in Capsules", exposing that some workshops in Hebei boiled leather waste into industrial gelatin and sold it to enterprises to make medicinal capsules. As soon as the program was broadcast, it caused an uproar. Since ancient times, people have died, and people have no faith. Is there any safe food in China after melamine? Are there any safe drugs in China after poison capsules?

3. Large chemical pharmaceutical enterprises have encountered great difficulties.

Drug-resistant orders and bidding for essential drugs affect chemical and pharmaceutical enterprises from the perspectives of demand and supply price, and large enterprises bear the brunt! In the cold winter of antibiotics, the performance of Harbin Pharmaceutical Co., Ltd., Shiyao Co., Ltd., Huayao Co., Ltd., Federal Pharmaceutical Co., Ltd., Xinhua Pharmaceutical Co., Ltd. and Lu Kang Co., Ltd. declined or even lost money. Large enterprises originally hoped to rely on the scale advantage to realize the "leftover" as king, but now they have to adjust their business ideas and implement strategic transformation.

4. Chinese medicine companies have tried the big health industry.

When the traditional business encounters the bottleneck of industrial policy or development space, it becomes a new topic for pharmaceutical enterprises to enter the big health industry through relevant diversification and build new growth points. Yunnan Baiyao and Tasly took the lead in breaking through and gained a lot. Guangyao, Tongrentang, Pien Tze Huang and Kang also tried the water. There are two main ways to enter the big health industry, one is to expand the core competence; The second is to monopolize resources.

5. Foreign pharmaceutical companies actively seek joint ventures and cooperation.

20 12 is a year for foreign pharmaceutical companies to accelerate their layout and layout in China. Pfizer and Shanghai are joint ventures, Xiansheng and Merck are joint ventures, and zhifei and Merck are in-depth cooperation. Prior to this, Sanofi acquired Sunstone, Naikeming acquired Pu Tian and Novartis acquired Tianyuan. Facing the rare policy environment, industrial opportunities and high-quality pharmaceutical assets, the actions of foreign companies are accelerating!

6. Industry mergers and acquisitions are gradually accelerating.

In 20 12, there were nearly 300 cases of mergers and acquisitions in China pharmaceutical industry, of which more than 60 cases exceeded 1 100 million yuan, and the merger and integration of pharmaceutical industry began to accelerate gradually. Typical cases include: China Resources Pharmaceutical acquired Shunfeng Pharmaceutical and Tianhe Pharmaceutical, Medtronic acquired Kang Hui Holdings, and Watsons Bio acquired Zerun in Shanghai and Daan in Hebei.

7. The new version of the list of essential drugs has expired.

In 2009, the National Measures for the Administration of Essential Drugs List stipulated that the list of essential drugs should be adjusted every three years, but the new version of the list of essential drugs has not kept up, which seems to be a long-standing project!

8. The primary health care system backfired.

According to China Health Statistics 20 12, the total number of people in primary health care systems such as township hospitals has dropped for two consecutive years. The six-in-one functional orientation is difficult to meet the medical needs of grassroots residents, and large clinical hospitals are still overcrowded, even to the next level!

9. Reform of payment methods of medical insurance.

The new payment methods of medical insurance include single disease payment, disease diagnosis related grouping-prepayment system (DRGs-PPS), total treatment prepayment and per capita payment. The solution is often a combination of multiple payment methods. The "pre-payment system" replaces the "post-payment system", medical expenses are changed from government control to hospital self-control, and drugs are changed from income-increasing means to cost items. Hospitals have the motivation to control medical expenses reasonably and choose the drugs with the highest cost performance.

10, Beijing Friendship Hospital leads the reform of public hospitals. On 201May 16, the "Beijing Public Hospital Reform Pilot Program" was promulgated and implemented, exploring the implementation of "two separation" (separation of management and administration, separation of medicine) and establishing "three mechanisms" (corporate governance operation mechanism, financial price compensation control mechanism and medical insurance payment mechanism) to further promote Beijing medical reform. Friendship Hospital is the only pilot public hospital in Beijing.